Cargando…
A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age
Inactivated influenza vaccines efficacy is variable and often poor. We conducted a phase 1 trial (NCT02188810), to assess the safety and immunogenicity of a novel nanoparticle Toll-like receptor 7/8 agonist adjuvant (Papaya Mosaic Virus) at different dose levels combined with trivalent influenza vac...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564144/ https://www.ncbi.nlm.nih.gov/pubmed/32698532 http://dx.doi.org/10.3390/vaccines8030393 |
_version_ | 1783595645428301824 |
---|---|
author | Langley, Joanne Pastural, Elodie Halperin, Scott McNeil, Shelly ElSherif, May MacKinnon-Cameron, Donna Ye, Lingyun Grange, Cécile Thibodeau, Valérie Cailhier, Jean-François Lapointe, Rejean McElhaney, Janet Martin, Luis Bolduc, Marilène Laliberté-Gagné, Marie-Eve Leclerc, Denis Savard, Pierre |
author_facet | Langley, Joanne Pastural, Elodie Halperin, Scott McNeil, Shelly ElSherif, May MacKinnon-Cameron, Donna Ye, Lingyun Grange, Cécile Thibodeau, Valérie Cailhier, Jean-François Lapointe, Rejean McElhaney, Janet Martin, Luis Bolduc, Marilène Laliberté-Gagné, Marie-Eve Leclerc, Denis Savard, Pierre |
author_sort | Langley, Joanne |
collection | PubMed |
description | Inactivated influenza vaccines efficacy is variable and often poor. We conducted a phase 1 trial (NCT02188810), to assess the safety and immunogenicity of a novel nanoparticle Toll-like receptor 7/8 agonist adjuvant (Papaya Mosaic Virus) at different dose levels combined with trivalent influenza vaccine in healthy persons 18–50 years of age. Hemagglutination-inhibition assays, antibody to Influenza A virus nucleoprotein and peripheral blood mononuclear cells for measurement of interferon-gamma ELISPOT response to influenza antigens, Granzyme B and IFNγ:IL-10 ratio were measured. The most common adverse events were transient mild to severe injection site pain and no safety signals were observed. A dose-related adjuvant effect was observed. Geometric mean hemagglutination-inhibition titers increased at day 28 in most groups and waned over time, but fold-antibody responses were poor in all groups. Cell mediated immunity results were consistent with humoral responses. The Papaya Mosaic Virus adjuvant in doses of 30 to 240 µg combined with reduced influenza antigen content was safe with no signals up to 3 years after vaccination. A dose-related adjuvant effect was observed and immunogenicity results suggest that efficacy study should be conducted in influenza antigen-naïve participants. |
format | Online Article Text |
id | pubmed-7564144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75641442020-10-26 A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age Langley, Joanne Pastural, Elodie Halperin, Scott McNeil, Shelly ElSherif, May MacKinnon-Cameron, Donna Ye, Lingyun Grange, Cécile Thibodeau, Valérie Cailhier, Jean-François Lapointe, Rejean McElhaney, Janet Martin, Luis Bolduc, Marilène Laliberté-Gagné, Marie-Eve Leclerc, Denis Savard, Pierre Vaccines (Basel) Article Inactivated influenza vaccines efficacy is variable and often poor. We conducted a phase 1 trial (NCT02188810), to assess the safety and immunogenicity of a novel nanoparticle Toll-like receptor 7/8 agonist adjuvant (Papaya Mosaic Virus) at different dose levels combined with trivalent influenza vaccine in healthy persons 18–50 years of age. Hemagglutination-inhibition assays, antibody to Influenza A virus nucleoprotein and peripheral blood mononuclear cells for measurement of interferon-gamma ELISPOT response to influenza antigens, Granzyme B and IFNγ:IL-10 ratio were measured. The most common adverse events were transient mild to severe injection site pain and no safety signals were observed. A dose-related adjuvant effect was observed. Geometric mean hemagglutination-inhibition titers increased at day 28 in most groups and waned over time, but fold-antibody responses were poor in all groups. Cell mediated immunity results were consistent with humoral responses. The Papaya Mosaic Virus adjuvant in doses of 30 to 240 µg combined with reduced influenza antigen content was safe with no signals up to 3 years after vaccination. A dose-related adjuvant effect was observed and immunogenicity results suggest that efficacy study should be conducted in influenza antigen-naïve participants. MDPI 2020-07-20 /pmc/articles/PMC7564144/ /pubmed/32698532 http://dx.doi.org/10.3390/vaccines8030393 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Langley, Joanne Pastural, Elodie Halperin, Scott McNeil, Shelly ElSherif, May MacKinnon-Cameron, Donna Ye, Lingyun Grange, Cécile Thibodeau, Valérie Cailhier, Jean-François Lapointe, Rejean McElhaney, Janet Martin, Luis Bolduc, Marilène Laliberté-Gagné, Marie-Eve Leclerc, Denis Savard, Pierre A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age |
title | A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age |
title_full | A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age |
title_fullStr | A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age |
title_full_unstemmed | A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age |
title_short | A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age |
title_sort | randomized controlled study to evaluate the safety and reactogenicity of a novel rvlp-based plant virus nanoparticle adjuvant combined with seasonal trivalent influenza vaccine following single immunization in healthy adults 18–50 years of age |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564144/ https://www.ncbi.nlm.nih.gov/pubmed/32698532 http://dx.doi.org/10.3390/vaccines8030393 |
work_keys_str_mv | AT langleyjoanne arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT pasturalelodie arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT halperinscott arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT mcneilshelly arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT elsherifmay arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT mackinnoncamerondonna arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT yelingyun arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT grangececile arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT thibodeauvalerie arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT cailhierjeanfrancois arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT lapointerejean arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT mcelhaneyjanet arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT martinluis arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT bolducmarilene arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT lalibertegagnemarieeve arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT leclercdenis arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT savardpierre arandomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT langleyjoanne randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT pasturalelodie randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT halperinscott randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT mcneilshelly randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT elsherifmay randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT mackinnoncamerondonna randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT yelingyun randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT grangececile randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT thibodeauvalerie randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT cailhierjeanfrancois randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT lapointerejean randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT mcelhaneyjanet randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT martinluis randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT bolducmarilene randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT lalibertegagnemarieeve randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT leclercdenis randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage AT savardpierre randomizedcontrolledstudytoevaluatethesafetyandreactogenicityofanovelrvlpbasedplantvirusnanoparticleadjuvantcombinedwithseasonaltrivalentinfluenzavaccinefollowingsingleimmunizationinhealthyadults1850yearsofage |